VYGR
VYGR
NASDAQ · Biotechnology

Voyager Therapeutics Inc

$3.50
-0.08 (-2.23%)
As of Jun 30, 10:24 PM ET ·
Financial Highlights (FY 2026)
Revenue
40.10M
Net Income
-118,893,512
Gross Margin
Profit Margin
-296.5%
Rev Growth
-0.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 40.1% 40.1%
Operating Margin -326.6% -293.9% -0.3% -0.3%
Profit Margin -296.5% -281.7% -0.3% -0.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 40.10M 40.27M 42.57M 38.58M
Gross Profit 17.06M 15.46M
Operating Income -130,935,936 -118,351,252 -137,767 -112,961
Net Income -118,893,512 -107,466,265 -129,666 -108,514
Gross Margin 40.1% 40.1%
Operating Margin -326.6% -293.9% -0.3% -0.3%
Profit Margin -296.5% -281.7% -0.3% -0.3%
Rev Growth -0.4% -0.4% +21.1% -3.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.86M 64.95M
Total Equity 186.28M 172.57M
D/E Ratio 0.31 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -126,902,125 -121,077,652 -158,434 -135,051
Free Cash Flow -114,389 -110,539